Corresponding Author: Paul A. Offit, MD, Division of Infectious Diseases, Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, 34th St & Civic Center Blvd, ARB, Room 1202C, Philadelphia, PA 19104-4399 (firstname.lastname@example.org).
Published Online: January 28, 2021. doi:10.1001/jama.2021.1114
Conflict of Interest Disclosures: None reported.
Editor’s Note: Although preprints are rarely included as references in JAMA articles, in the midst of the COVID-19 pandemic some of the information in this article is based on rapidly developing and emerging science that is only available as preliminary communications on preprint servers.
X , Zou
J , Fontes-Garfias
et al Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv
. Preprint posted online January 7, 2021. doi:10.1101/2021.01.07.425740Google Scholar
K , Werner
AP , Moliva
et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. BioRxiv
. Preprint posted online January 25, 2021. doi:10.1101/2021.01.25.427948Google Scholar
Z , Schmidt
F , Weisblum
et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv
. Preprint posted online January 19, 2021. doi:10.1101/2021.01.15.426911Google Scholar
CK , Ayres
F , Hermanus
et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv
. Preprint posted online January 19, 2021. doi:10.1101/2021.01.18.427166Google Scholar